Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 7/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549393 | 0.92 | ALDH1A1 (0.44) | ALDH1A1HPGDHTR2CCNR1LMNA | |
| SCHEMBL3405777 | 0.88 | HTR2C (0.50) | ALDH1A1HPGDHTR2CCNR1LMNA | |
| SCHEMBL3399406 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HPGDHTR2CCNR1LMNA | |
| SCHEMBL3398917 | 0.83 | HRH3 (0.45) | ALDH1A1HTR2CLMNAKMT2AL3MBTL1 | |
| SCHEMBL5549408 | 0.83 | HRH3 (0.45) | ALDH1A1HTR2CLMNAKMT2AL3MBTL1 | |
| SCHEMBL3398941 | 0.83 | CNR1 (0.47) | ALDH1A1HPGDHTR2CCNR1LMNA | |
| SCHEMBL3398825 | 0.83 | SCN5A (0.54) | ALDH1A1HPGDCNR1LMNASMN1; SMN2 | |
| SCHEMBL3404822 | 0.82 | THRA (0.50) | ALDH1A1HPGDHTR2CCNR1LMNA | |
| SCHEMBL3404938 | 0.82 | HTR2C (0.48) | ALDH1A1HPGDHTR2CCNR1LMNA | |
| SCHEMBL3401632 | 0.82 | HTR2C (0.46) | ALDH1A1HPGDHTR2CCNR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | ALDH1A1 916/4885HPGD 1057/4885HTR2C 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.